Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Marie H. Kristiansen, Vibe Skov, Lasse Kjær, Morten Kranker Kranker Larsen, Christina Ellervik, Hans Carl Hasselbalch, Troels Wienecke

Blood (2022) 140 (Supplement 1): 3949–3950.

https://doi.org/10.1182/blood-2022-156629

Published: 2022

Journal Articles

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Morten Kranker Kranker Larsen, Vibe Skov, Lasse Kjær, Henrik E. Poulsen, Christina S. Eickhardt-Dalbøge, Trine A. Knudsen, Sarah F. Christensen, Anders L. Sørensen, Marie H. Kristiansen, Troels Wienecke, Rasmus K. Pedersen, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl, Christina Ellervik, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6842–6843.

https://doi.org/10.1182/blood-2022-165252

Published: 2022

Journal Articles

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Anders Lindholm Lindholm Sørensen, Vibe Skov, Lasse Kjær, Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Morten Kranker Larsen, Claus Nielsen, Carsten Thomsen, Lise Mette Rahbek Gjerdrum, Trine Alma Knudsen, Christina Ellervik, Ulrik Malthe Overgaard, Christen Lykkegaard Andersen, Mads Emil Bjørn, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6806–6807.

https://doi.org/10.1182/blood-2022-157397

Published: 2022

Journal Articles

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger

Blood (2022) 140 (Supplement 1): 9663–9664.

https://doi.org/10.1182/blood-2022-156889

Published: 2022

Journal Articles

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Laura Massarenti, Trine A. Knudsen, Christian Enevold, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Claus Henrik Nielsen, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 3862–3863.

https://doi.org/10.1182/blood-2022-157936

Published: 2022

Journal Articles

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Vibe Skov, Mads Thomassen, Lasse Kjær, Morten Kranker Larsen, Christina Ellervik, Trine Alma Knudsen, Torben A. Kruse, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 9604–9605.

https://doi.org/10.1182/blood-2022-157906

Published: 2022

Journal Articles

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Lee O'Brien Andersen, Henrik V Nielsen, Kurt Fuursted, Christen Rune Stensvold, Morten Kranker Larsen, Lasse Kjær, Sarah F. Christensen, Trine A. Knudsen, Vibe Skov, Christina Ellervik, Lars Rønn Olsen, Hans Carl Hasselbalch, Xiaohui Chen Nielsen, Jens Jørgen Elmer Christensen

Blood (2022) 140 (Supplement 1): 12178–12179.

https://doi.org/10.1182/blood-2022-166031

Published: 2022

Journal Articles

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms

Hans Carl Hasselbalch, Margitta Elvers, Andrew I. Schafer

Blood (2021) 137 (16): 2152–2160.

https://doi.org/10.1182/blood.2020008109

Published: 2021

Journal Articles

The Association between Circulating Inflammatory Markers and Metabolic Syndrome: A General Population Study

Kasper Mønsted Pedersen, MD, Sabrina Cordua, MD, Hans Carl Hasselbalch, Professor, dr.MD, Christina Ellervik, Associate Professor, MD PhD

Blood (2018) 132 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2018-99-120356

Published: 2018

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

Vibe Skov, PhD, Lasse Kjær, PhD, Mads Thomassen, PhD, Steffen Koschmieder, MD, Julia Czech, Nicolas Chatain, PhD, Niels Pallisgaard, Sabrina Cordua, MD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4327.

https://doi.org/10.1182/blood-2018-99-119158

Published: 2018

Journal Articles

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2018-99-110602

Published: 2018

Journal Articles

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

Vibe Skov, PhD, Katrine LM Schmidt, Kasper Mønsted Pedersen, MD, Bettina Hansen, Tobias Wirenfeldt Klausen, M.S., Torben A Kruse, Mads Thomassen, PhD, Lasse Kjær, PhD, Christina Ellervik, Associate Professor, MD PhD, Morten Holmstrøm, MD, Bjørn Nexø, Hans Carl Hasselbalch, Professor, dr.MD, Magdalena J Laska

Blood (2018) 132 (Supplement 1): 5488.

https://doi.org/10.1182/blood-2018-99-118080

Published: 2018

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2018-99-118690

Published: 2018

Journal Articles

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5491.

https://doi.org/10.1182/blood-2018-99-117122

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Arpad Illes, MD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, Professor, dr.MD, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 579.

https://doi.org/10.1182/blood-2018-99-118715

Published: 2018

Journal Articles

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2018-99-117981

Published: 2018

Journal Articles

Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation

Julia Czech, Sabrina Cordua, Barbora Weinbergerova, Lijuan Han, Claudia Schubert, Tim H. Brümmendorf, MD, Jiri Mayer, Prof, MD SCs, Zdenek Racil, MD, Blanka Kubesova, MSc, Trine Alma Knudsen, MD, Anders Sørensen, Morten Holmstrøm, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Thomas Stauffer Larsen, MD PhD, Hans Carl Hasselbalch, MD Professor, DMSc, Nicolas Chatain, Steffen Koschmieder

Blood (2017) 130 (Supplement 1): 4194.

https://doi.org/10.1182/blood.V130.Suppl_1.4194.4194

Published: 2017

NARROW

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms

The Association between Circulating Inflammatory Markers and Metabolic Syndrome: A General Population Study

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only